Breaking Down China Zhenhua (Group) Science & Technology Co., Ltd Financial Health: Key Insights for Investors

Curious whether China Zhenhua Science & Technology (000733.SZ) is a bargain, a fortress or a turnaround story? In Q3 2025 the company posted revenue of CNY 1.516 billion-up 15.78% year-over-year-while TTM revenue as of Sept 30, 2025 stood at CNY 5.41 billion (down 1.71% YoY) after annual revenue slid to CNY 5.22 billion in 2024 from CNY 7.79 billion in 2023; profitability showed a Q3 net profit attributable to shareholders of CNY 311 million (up 38.68% YoY) but nine‑month net profit of CNY 623 million was down 3.31% YoY and basic EPS for the first nine months fell to CNY 1.1245 from CNY 1.1635, leaving TTM net income at CNY 948.82 million and returns at ROE 6.39% and ROA 3.24%; the balance sheet packs liquidity and low leverage with total debt of CNY 1.01 billion versus cash and equivalents of CNY 3.23 billion (net cash), a debt‑to‑equity ratio of 0.06, debt coverage 102.6% and interest coverage of 36.41, while short‑term assets of CNY 14.8 billion outstrip short‑term liabilities of CNY 2.7 billion yielding a current ratio 5.42 and a quick ratio of 4.48, operating cash flow of CNY 1.60 billion comfortably covering capex of CNY 463 million and translating into strong free cash flow; market valuation sits at a market cap of CNY 27.46 billion (Dec 16, 2025) with TTM P/E 28.94 (forward 25.61), EV/EBITDA 23.62, P/S 5.08, P/B 1.80 and EV/Sales 4.32, while potential headwinds include exposure to defense/state sectors, a revenue drop from CNY 7.79 billion to CNY 5.22 billion and net profit decline from CNY 970 million to CNY 623 million, offset by conservative leverage (D/E down from 30.4% to 5.8% over five years), a rock‑solid cash position and analyst forecasts of robust expansion-earnings and revenue are projected to grow 24% and 17.9% per annum respectively-so read on to unpack what these figures mean for investors and which signals matter most for your portfolio.

China Zhenhua Science & Technology Co., Ltd (000733.SZ) - Revenue Analysis

• Q3 2025 revenue: CNY 1.516 billion - up 15.78% year-over-year (Q3 2024 comparable).
• TTM revenue as of 30 Sep 2025: CNY 5.41 billion - down 1.71% YoY on a trailing-12-month basis.
• Full-year 2024 revenue: CNY 5.22 billion - a 32.99% decline from CNY 7.79 billion in 2023.
• Revenue per employee: ~CNY 764,162 (7,074 employees).
• Market capitalization (16 Dec 2025): CNY 27.46 billion; P/S ratio: 5.08.

• The Q3 2025 uplift suggests improving quarterly momentum, but TTM and FY 2024 declines highlight uneven recovery and lapping effects from 2023's higher base.
• A P/S of 5.08 implies the market is pricing a premium to current revenue; investors should compare this to peers and historical multiples to assess valuation risk.
• Revenue per employee (~CNY 764k) can be used as an operational efficiency benchmark against sector peers; workforce scale (7,074) affects fixed-cost leverage and margin potential.

China Zhenhua Science & Technology Co., Ltd (000733.SZ) - Profitability Metrics

• Q3 2025 net profit attributable to shareholders: CNY 311 million (up 38.68% YoY).
• Net profit for first nine months (9M) 2025: CNY 623 million (down 3.31% YoY).
• Basic EPS, 9M ended Sep 30, 2025: CNY 1.1245 (vs. CNY 1.1635 in 9M 2024).
• TTM net income (as of Sep 30, 2025): CNY 948.82 million.
• Return on Equity (ROE): 6.39%.
• Return on Assets (ROA): 3.24%.

• Interpretation cues: the sizable Q3 uplift suggests improving margins or one-off gains in the quarter, while 9M declines and EPS compression indicate uneven performance across the year.
• ROE and ROA imply moderate capital efficiency relative to higher-return peers; further analysis of leverage, margin drivers, and non-recurring items is warranted.

China Zhenhua Science & Technology Co., Ltd (000733.SZ) - Debt vs. Equity Structure

• Debt-to-equity ratio: 0.06 (6%), indicating a very low level of debt relative to shareholders' equity.
• Total debt: CNY 1.01 billion; Cash and equivalents: CNY 3.23 billion - net cash position of CNY 2.22 billion.
• Debt coverage ratio: 102.6% - operating cash flow is sufficient to cover debt obligations.
• Interest coverage ratio: 36.41 - strong ability to service interest expenses from operating earnings.
• Five-year trend: debt-to-equity reduced from 30.4% to 5.8%, reflecting materially improved financial leverage and deleveraging efforts.

• Financial stability: Net cash and high interest coverage reduce refinancing risk and increase tolerance for cyclical earnings volatility.
• Strategic flexibility: Low leverage enables opportunistic M&A, R&D investment, or shareholder returns without immediate financing constraints.
• Risk profile: Minimal debt lowers default and covenant risks but may imply conservative capital deployment; management can choose to optimize capital structure if return-on-invested-capital targets warrant.

China Zhenhua Science & Technology Co., Ltd (000733.SZ) - Liquidity and Solvency

• Current ratio: 5.42 - strong short‑term financial health.
• Quick ratio: 4.48 - sufficient liquid assets to cover immediate liabilities.
• Short‑term assets: CNY 14.8 billion vs. short‑term liabilities: CNY 2.7 billion.
• Long‑term assets: CNY 14.8 billion vs. long‑term liabilities: CNY 671.5 million.
• Operating cash flow: CNY 1.60 billion; Capital expenditures: CNY 463 million.
• Low debt levels and substantial cash reserves supporting solvency.

• Operating cash flow covers CapEx by ~3.46x (1.60bn / 0.463bn), supporting reinvestment and liquidity buffer.
• Net short‑term cushion: CNY 12.1 billion (14.8bn - 2.7bn).
• Net long‑term cushion: CNY 14.1285 billion (14.8bn - 0.6715bn).

China Zhenhua Science & Technology Co., Ltd (000733.SZ) - Valuation Analysis

This section presents the key valuation metrics for China Zhenhua Science & Technology Co., Ltd (000733.SZ), current as of the referenced data points, and interprets what they imply for investors evaluating relative value, growth expectations and balance-sheet support.

• Premium multiple profile: TTM P/E of 28.94 and EV/EBITDA of 23.62 indicate the market is pricing growth and/or moat premium versus lower-multiple peers.
• Improving forward outlook: Forward P/E (25.61) is lower than TTM P/E, signaling analyst-expected EPS growth or margin improvement embedded in current prices.
• Revenue valuation: P/S of 5.08 and EV/Sales of 4.32 show investors assign a high value to each yuan of revenue - important for companies where revenue growth is a key driver of returns.
• Balance-sheet cushion: P/B of 1.80 implies the stock trades modestly above book value, providing some downside support compared with high P/B names.

Key interpretive considerations for investors:

• Compare these multiples to sector and peer medians to assess relative expensiveness; elevated EV/EBITDA suggests limited margin upside priced in or a higher-growth expectation.
• Watch earnings revisions - the reduction from TTM to forward P/E depends on forecasted EPS increases; negative revisions would reverse this improvement.
• Liquidity and capital structure effects: EV-based multiples (EV/EBITDA, EV/Sales) account for debt and cash - important where leverage or cash positions swing enterprise value materially.
• Market-cap context: CNY 27.46 billion market cap places the company in mid-cap range on the SZSE; index inclusion, free-float and institutional ownership dynamics can amplify multiple compression or expansion.

For additional investor context and ownership dynamics, see: Exploring China Zhenhua (Group) Science & Technology Co., Ltd Investor Profile: Who's Buying and Why?

China Zhenhua Science & Technology Co., Ltd (000733.SZ) - Risk Factors

Investors assessing China Zhenhua Science & Technology Co., Ltd (000733.SZ) should weigh several concentrated risks that arise from its business mix, recent financial trajectory, market behavior, and balance-sheet profile.

• Geopolitical and sovereign concentration: meaningful exposure to China's defense sector and state-owned enterprise customers concentrates revenue risk and links performance to government procurement cycles and geopolitical developments.
• Revenue contraction: reported revenue fell from CNY 7.79 billion (2023) to CNY 5.22 billion (2024), signaling challenges in maintaining topline growth and potential pressure on margins and cash generation.
• Profitability deterioration: net profit declined from CNY 970 million (2023) to CNY 623 million (2025), pointing to margin compression, cost pressures, contract timing, or one-off items affecting net income.
• Extremely low market sensitivity: a beta of 0.055 indicates the stock has historically exhibited very low volatility relative to the broader market, which can reduce upside capture in bullish markets and limit market-based price discovery.
• Leverage improvement but remaining dependency risks: debt-to-equity has fallen from 30.4% to 5.8% over five years, reflecting stronger financial leverage management, yet customer concentration and contract timing still pose liquidity execution risks.
• Balance-sheet liquidity: substantial cash reserves reported by the company provide financial stability and strategic flexibility to weather procurement cycle swings or pursue opportunistic investments.

Key quantitative metrics and trend snapshot:

Risk-management considerations for investors include contract diversification, margin drivers, scenario planning for procurement slowdowns, and sensitivity of valuation to low beta. For the company's articulated strategic context and guiding principles see: Mission Statement, Vision, & Core Values (2026) of China Zhenhua (Group) Science & Technology Co., Ltd.

China Zhenhua Science & Technology Co., Ltd (000733.SZ) - Growth Opportunities

• Analyst forecasts: earnings per share (EPS) expected to grow ~24% per annum; revenue expected to grow ~17.9% per annum.
• Product focus: high-reliability electronic components targeted at China's strategic industries (defense, aerospace, energy, telecom), driving durable end-market demand and pricing power.
• Vertical integration: upstream-to-downstream control improves margin resilience and shortens lead times, supporting margin expansion as volumes scale.
• Balance sheet strength: low debt profile combined with substantial cash reserves provides optionality for M&A, R&D, capacity expansion, or downside protection during cyclical contractions.
• Cash generation: strong operating cash flow versus capital spending underpins free cash flow conversion, enabling reinvestment without equity dilution.

• Free cash flow strength: with CNY 1.60 billion in operating cash flow versus CNY 463 million in capex, FCF generation (~CNY 1.137 billion) supports dividends, buybacks, or strategic investment.
• Capital flexibility: substantial cash reserves mean the company can pursue bolt-on acquisitions or accelerate capacity for fast-growing product lines without increasing leverage materially.
• Risk-mitigating structure: vertical integration reduces supplier concentration risk and improves gross margin stability during supply shocks.